Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum

Summary

The purpose of this Phase 2a, open label, proof-of-concept clinical study is to assess the efficacy and safety of etrasimod (APD334) in patients with Pyoderma Gangrenosum.

Timeline

Start

2017-06-07

Primary completion

2018-05-22

Completion

2018-05-22

Outcome

Outcome not reported

Stopped (Business): “Terminated \[Sponsor decision to terminate the study\]”

Drugs

Indications